Literature DB >> 18056992

A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.

Katerina Sidera1, Maria Gaitanou, Dimitris Stellas, Rebecca Matsas, Evangelia Patsavoudi.   

Abstract

HSP90 is a ubiquitously expressed molecular chaperone that controls the folding, assembly, intracellular disposition, and proteolytic turnover of many proteins, most of which are involved in signal transduction processes. Recently, a surface form of HSP90 has been identified and associated with cell migration events. In this paper, we explore the interaction of surface HSP90 with HER-2, a receptor-like glycoprotein and member of the ErbB family of receptor tyrosine kinases that play central roles in cellular proliferation, differentiation, and migration as well as in cancer progress. The involvement of HSP90 in the regulation of HER-2 has been attributed so far to receptor stabilization via interaction with its cytoplasmic kinase domain. Here we present evidence, using glutathione S-transferase pull-down and transfection assays, for a novel interaction between surface HSP90 and the extracellular domain of HER-2. Specific disruption of this interaction using mAb 4C5, a function-blocking monoclonal antibody against HSP90, inhibits cell invasion accompanied by altered actin dynamics in human breast cancer cells under ligand stimulation conditions with heregulin. Additionally, disruption of surface HSP90/HER-2 interaction leads to inhibition of heregulin-induced HER-2-HER-3 heterodimer formation, reduced HER-2 phosphorylation, and impaired downstream kinase signaling. Interestingly, this disruption does not affect HER-2 internalization. Our data suggest that surface HSP90 is involved in heregulin-induced HER-2 activation and signaling, leading to cytoskeletal rearrangement, essential for cell invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056992     DOI: 10.1074/jbc.M701803200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  A chemical cross-linking method for the analysis of binding partners of heat shock protein-90 in intact cells.

Authors:  Shaoming Song; Sutapa Kole; Michel Bernier
Journal:  Biotechniques       Date:  2012-04       Impact factor: 1.993

2.  Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-06-05       Impact factor: 6.166

3.  Secreted heat shock protein 90α (HSP90α) induces nuclear factor-κB-mediated TCF12 protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion.

Authors:  Wei-Shone Chen; Chia-Chi Chen; Li-Li Chen; Chun-Chung Lee; Tze-Sing Huang
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

Review 4.  Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.

Authors:  Wei Li; Fred Tsen; Divya Sahu; Ayesha Bhatia; Mei Chen; Gabriele Multhoff; David T Woodley
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

Review 5.  Secreted heat shock protein-90 (Hsp90) in wound healing and cancer.

Authors:  Wei Li; Divya Sahu; Fred Tsen
Journal:  Biochim Biophys Acta       Date:  2011-09-25

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 7.  Impact of heat-shock protein 90 on cancer metastasis.

Authors:  Shinji Tsutsumi; Kristin Beebe; Len Neckers
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

8.  Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2.

Authors:  Weihua Li; Xiaohui Miao; Zhongtian Qi; Wenting Zeng; Jianxin Liang; Zengwei Liang
Journal:  Virol J       Date:  2010-02-20       Impact factor: 4.099

9.  Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits.

Authors:  Dimitris Stellas; Avraam El Hamidieh; Evangelia Patsavoudi
Journal:  BMC Cell Biol       Date:  2010-07-05       Impact factor: 4.241

10.  Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption.

Authors:  Yongfeng Shao; Bingchan Wang; Dorothy Shi; Suyu Miao; Panneerselvam Manivel; Ramadas Krishna; Yiding Chen; Y Eric Shi
Journal:  Mol Oncol       Date:  2014-06-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.